Alport Syndrome clinical trials

Explore recruiting alport syndrome clinical trials.

Recruiting alport syndrome studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Alport Syndrome trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

(22419) A randomized, double-blind, placebo-controlled, parallel group Phase 2a study with an extension phase to evaluate the efficacy and safety of BAY 3401016 in participants aged 18 to 45 with Alport syndrome

Spain, Italy, Poland, Czechia, Germany, Portugal +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Vonafexor fixed dose-escalation safety and proof-of-concept study in patients with at risk of progression Alport syndrome

Spain, France, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

DOUBLE PRO-TECT Alport: A confirmatory, multicenter, randomized, double-blind, placebo-controlled clinical trial to assess the effect of Dapagliflozin on the progression of chronic kidney disease in adolescent and young adult patients with Alport syndrome

Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A study to learn how safe the study treatment BAY3401016 is, how it affects the body and how it moves into, through, and out of the body when a single amount is given to healthy male participants

Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the NOX1/4 Inhibitor Setanaxib in Patients with Alport Syndrome

Spain, Czechia, France, Austria, Lithuania, Slovakia

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis

France, Belgium, Netherlands, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Alport Syndrome trials by city

Alport Syndrome in Toronto Alport Syndrome in Vancouver Alport Syndrome in Montreal Alport Syndrome in Calgary Alport Syndrome in Edmonton Alport Syndrome in Ottawa Alport Syndrome in Winnipeg Alport Syndrome in Quebec City Alport Syndrome in Hamilton Alport Syndrome in Kitchener Alport Syndrome in London Alport Syndrome in Halifax Alport Syndrome in New York Alport Syndrome in Los Angeles Alport Syndrome in Chicago Alport Syndrome in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease